195 related articles for article (PubMed ID: 21127454)
1. Impact of therapeutic drug monitoring of voriconazole in a pediatric population.
Brüggemann RJ; van der Linden JW; Verweij PE; Burger DM; Warris A
Pediatr Infect Dis J; 2011 Jun; 30(6):533-4. PubMed ID: 21127454
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
Gerin M; Mahlaoui N; Elie C; Lanternier F; Bougnoux ME; Blanche S; Lortholary O; Jullien V
Ther Drug Monit; 2011 Aug; 33(4):464-6. PubMed ID: 21743382
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
5. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
6. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age.
Shima H; Miharu M; Osumi T; Takahashi T; Shimada H
Pediatr Blood Cancer; 2010 Jul; 54(7):1050-2. PubMed ID: 20146339
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole concentrations and outcome of invasive fungal infections.
Miyakis S; van Hal SJ; Ray J; Marriott D
Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
9. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
10. [Level of evidence for therapeutic drug monitoring of voriconazole].
Hulin A; Dailly E; Le Guellec C;
Therapie; 2011; 66(2):109-14. PubMed ID: 21635857
[TBL] [Abstract][Full Text] [Related]
11. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis.
Choi SH; Lee SY; Hwang JY; Lee SH; Yoo KH; Sung KW; Koo HH; Kim YJ
Pediatr Blood Cancer; 2013 Jan; 60(1):82-7. PubMed ID: 22887791
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.
Pieper S; Kolve H; Gumbinger HG; Goletz G; Würthwein G; Groll AH
J Antimicrob Chemother; 2012 Nov; 67(11):2717-24. PubMed ID: 22796890
[TBL] [Abstract][Full Text] [Related]
13. Voriconazole plasma monitoring.
Pasqualotto AC; Shah M; Wynn R; Denning DW
Arch Dis Child; 2008 Jul; 93(7):578-81. PubMed ID: 18252755
[TBL] [Abstract][Full Text] [Related]
14. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory.
Miyakis S; van Hal SJ; Solvag CJ; Ray J; Marriott D
Ther Drug Monit; 2010 Oct; 32(5):661-4. PubMed ID: 20720520
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients.
Rüping MJ; Müller C; Vehreschild JJ; Böhme A; Mousset S; Harnischmacher U; Frommolt P; Wassmer G; Drzisga I; Hallek M; Cornely OA
Mycoses; 2011 May; 54(3):230-3. PubMed ID: 19889174
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients.
Gómez-López A; Cendejas-Bueno E; Cuesta I; García Rodríguez J; Rodríguez-Tudela JL; Gutiérrez-Altés A; Cuenca-Estrella M
Med Mycol; 2012 May; 50(4):439-45. PubMed ID: 22070341
[TBL] [Abstract][Full Text] [Related]
17. Determination of saliva trough levels for monitoring voriconazole therapy in immunocompromised children and adults.
Michael C; Bierbach U; Frenzel K; Lange T; Basara N; Niederwieser D; Mauz-Körholz C; Preiss R
Ther Drug Monit; 2010 Apr; 32(2):194-9. PubMed ID: 20216120
[TBL] [Abstract][Full Text] [Related]
18. [Treatment with voriconazole for invasive fungal infection during chemotherapy for leukemia: doses and plasma concentration of voriconazole in children].
Fukushima K; Fujisawa M; Nakajima D; Matsunaga T; Hagisawa S; Kurosawa H; Sugita K; Arisaka O
Rinsho Ketsueki; 2007 May; 48(5):402-6. PubMed ID: 17571586
[TBL] [Abstract][Full Text] [Related]
19. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.
Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G
Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523
[TBL] [Abstract][Full Text] [Related]
20. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
Trifilio S; Ortiz R; Pennick G; Verma A; Pi J; Stosor V; Zembower T; Mehta J
Bone Marrow Transplant; 2005 Mar; 35(5):509-13. PubMed ID: 15654347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]